Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel

[Hopeful]

Abstract:

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_744

Poster:

http://www.abstracts2view.com/sabcs10/viewp.php?nu=P3-14-04

Hopeful

[Rich66]

Discussion: High clinical responses were observed in patients with Her2+ breast cancer, including the first-line subset and patient subsets with prior Her2-directed, endocrine, and taxane therapies. The combination of neratinib 240 mg and paclitaxel 80 mg/m²was tolerable, with a toxicity profile similar to each drug given as monotherapy. A phase 3 trial is ongoing to study this combination in the first-line setting compared with trastuzumab plus paclitaxel.